From: @modernatx.com; To 51) @niodematx.com GALLINA Sandra (SANTE) (SANTE): SG-RECOVER): Cc: SANTE)

Subject: RE: Our comments

Date: mardi 24 novembre 2020 18:39:08

an Version 11.24.20).DOCX Attachmente: Annex 8 - APA GENERAL DRAFT CONTRACT REV

Annex 8 - APA GENERAL DRAFT CONTRACT REV 11,24,20),DOCX

Dear colleagues:

Please find attached the following documents:

1. Revised draft of the APA with the following proposed minor edits:



2 Clean version of the APA

We remain available at your request to address any questions or concerns you may have. Thank you for the tremendous effort to finalize today!

Kind regards,

From:	@ec.europa eu	@ec.europa.eu>
Sent: Tuesd	av, November 24, 2020 11:37 AM	
To:		@modernatx.com;
	@modernatx com	
Cc	@ec.europa.eu;	@ec.europa.eu;
	@ec.europa.eu;	@ec.europa.eu*
	ec.europa.eu;	@ec europa.eu;

Subject: RE: Our comments

Dear colleagues,

Please find enclosed our final comments on the draft. All your edits are accepted including the In our discussion today with the Member States your We have only added some edits on the vaccine arder form Apart from that our inter service process brought about As already mentioned to during our phone call earlier today, we would need a

clean version from ideally within the next two hours to secure early adoption by the Commission

tomorrow morning and subsequent notification to the Member States still in the afternoon. It appears that two Member States have a public holiday which means that we have to wait six working days instead of five to be able to proceed to signature.

Thank you for the excellent cooperation!





Subject: RE: Our comments

Thank you very much for your email. Please find attached a revised draft with light edits to the agreement and the inclusion of the various annexes. We are available to discuss at your request in order to finalize the agreement.

Thank you very much for your time and continued consideration on behalf of Moderna.

Kind regards,

Dear colleagues,

Please find enclosed our edits. I would note in particular

- the proposed language
- _
- •
- the annex has not been reviewed as I sent you comments separately
- Annexes are still missing.

Member States most likely in the afternoon CET tomorrow and we will have to explain

I would be very important if you could
confirm by around 11am CET tomorrow that on your side there are no outstanding
issues and that you are able to provide us with a complete clean text including all
annexes. I will wake up early tomorrow morning to check my mails should there be any
open issues. I ust in case; my cell phone is
endorsement by all Member States, we might be able to proceed with adoption by the
Commission either on Wednesday or Thursday but for that we obviously need an agreed
text. Should a minor typo like issue emerge later, we can still fix it prior to signature.

For the avoidance of doubt, unless we have commented on your edits, we agree with them.

Let's now give it the last push!

@modernatx.com> Sent: Monday, November 23, 2020 7:29 PM Tot SJ) < @ec europa eu>: @modernatx.com> Subject: RE: quick question on logistics thank you very much for the follow-up document from this d is endorsed by Moderna – please consider that our draft. We are waiting for your comments as the next step, and look forward to reviewing those and finalizing the document as soon as you are able to send. Best, **I Moderna** @modernatx.com | modernatx.com Mobile Fmail:

Sent: Monday, November 23, 2020 1:06 PM

@ec.europa eu <

@ec.europa.eu>

From:

To: modernatx.com>:

@modernatx.com>

Subject: quick question on logistics

EXTERNAL

We have been reviewing draft and have spotted a few cross reference etc, issues. Lalso note a few questions addressed to us. Ljust wanted to check whether you are waiting for our comments first because we are waiting for your confirmation on whether draft is endorsed by Moderna.

Best.



🚣 Please consider the environment before printing this email

Confidentiality notice and disclaimen: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person,

This message was sent from

designated recipient(s). It may contain confidential or proprietary information and may be subject to the attorney-client privilege or other confidentiality protections. If you are not a designated recipient, you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.